AsthmaHAP3NCT04023422
Clinic Navigation and Home Visits to Improve Guideline-based Care and Outcomes in Low Income Minority Adults With Asthma
A study testing Clinical intervention and Feedback in people with Asthma, run by University of Pennsylvania at 2 sites in United States.
Trial summary
Asthma-related deaths are more numerous among low-income minority patients and older adults with chronic diseases. Guidelines for asthma management have not addressed the needs of these groups. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Asthma
- What is being tested?
- Clinical intervention and Feedback
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 367 participants
- Where
- 2 sitesUnited States
- Study dates
- 21 Aug 2019to 30 Apr 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Female or male > 18 years and living in a Philadelphia neighborhood in which at least 20% of households have incomes below the federal poverty level (19104, 19120, 19121, 19122, 19124, 19125, 19131, 19132, 19133, 19134, 19139, 19140, 19141, 19142, 19143, 19144, 19145, 19146, 19153, 19151)
- A patient in a participating clinic
- Doctor's diagnosis of asthma
- Prescribed an inhaled corticosteroid for asthma
- Required prednisone or an Emergency Department (ED) visit or hospitalization for asthma within 12 months before enrollment.
- Some patients with a diagnosis of asthma and prescribed inhaled corticosteroid may also have mention of Chronic Obstructive Pulmonary Disease (COPD) in their record, particularly if they smoke. Asthma and COPD are both heterogeneous diseases, and may be impossible to distinguish by clinical characteristics.Both COPD and asthma can have evidence of reversible obstruction and also of irreversible obstruction. It is important not to exclude these patients, sometimes called overlap patients as they may benefit from these interventions.
Who cannot join
- Severe psychiatric or cognitive problems making it impossible to understand or carry out the protocol;
- Excluded are those with other chronic lung diseases: lung cancer, cystic fibrosis, heart failure, chronic bronchitis, pulmonary hypertension, a candidate or recipient for lung transplant, a history of bronchial thermoplasty.
- Excluded are those with more than 20 pack year tobacco use.
Trial locations and contacts
2 sites in 1 country.
United States2 sites
University of Pennsylvania Health Center
Philadelphia, Pennsylvania, 19104
University of Pennsylvania Health System
Philadelphia, Pennsylvania, 19104
About this study
Asthma-related deaths are more numerous among low-income minority patients and older adults with chronic diseases. Guidelines for asthma management have not addressed the needs of these groups. The investigators recently demonstrated the feasibility, acceptability, and evidence of effectiveness of two interventions to improve access to care, patient-provider communication, and asthma outcomes: 1) CI: clinic intervention using a patient advocate to prepare for, attend, and confirm understanding of an office visit, and 2) HV: home visits for care coordination and informing clinicians of home barriers to managing asthma is associated with subsequent improvement in asthma outcomes. This project explores whether these interventions can be combined for greater effectiveness, delivery of guideline-based asthma care, and outcomes in low-income minority patients.
In a randomized controlled factorial trial, 400 adults with uncontrolled asthma living in low-income urban neighborhoods are offered 18-months' participation: 12 months of clinical intervention and 6 months of evaluation to monitor sustainability of interventions and outcomes. Patients will be randomized to 1) a patient advocate and (2) an advocate and home visits, (3) an advocate and real-time feedback to the asthma provider (clinician) at each clinic visit of guidelines-relevant relevant information, and 4) (2), and (3). Interventions will be delivered by a community health worker. The study estimates Specific Aim 1: improvement over time of within-group (before-after in four groups) asthma outcomes (asthma control, quality of life, ED visits, hospitalizations, prednisone bursts) Specific Aim 2: across group differences in improvement over time in asthma outcomes; Specific Aim 3: the costs associated with each of the interventions. A cost-offset analysis will determine which intervention costs are offset by savings attributable to reductions in ED, hospitalization or other visits for asthma control and other outcomes.
Read more
Exploratory Aim: changes in behavior from the interventions using interviews of clinicians and patients.
Investigators hypothesize that improved outcomes in asthma patients will result from enhanced patient-clinician communication, clinician attention to home environmental exposures, and clinician consideration of the guidelines, at a program cost offset by lower patient health care utilization.
Read the detailed description
Asthma, a chronic but treatable disease, affects 18.7 million US adults. Asthma-related deaths, hospitalizations, and ED visits are more prevalent in low-income and minority patients, especially African Americans and particularly among older adults, many with co-morbidities.
The Expert Panel Report 3 (EPR3) Guidelines for Asthma Diagnosis and Management, currently undergoing revision, is primarily directed at children and young adults. It overlooks older patients, many with comorbidities and many who live in poverty. Action plans are infrequently used and their benefits, strongly recommended by guidelines, have not been evaluated in older or low-income minority adults. Regular use of inhaled steroids, endorsed by the Guidelines for all but the mildest asthma is limited by social and economic barriers, e.g. cost and accessibility of medication. Failure of guidelines to address the barriers of poverty, limited education, poor housing and communication infrastructure, and suboptimal public transportation may promote non-adherence by clinicians.
For these vulnerable adults, the investigators recently demonstrated the feasibility, acceptability, and evidence of effectiveness of two separate interventions to improve access to care, patient-provider communication, and asthma outcomes: 1) a patient advocate (PA) (HAP2 Study (R18 HL116285)) to prepare for, attend, and confirm understanding of an office visit, and 2) community health workers (CHWs) (ARC Study (PCORI AS 1307-05218)) to assess home barriers to asthma management and coordinate care between home and clinic. Both protocols, well-accepted by patients and clinicians, allow prompting, delivery, and testing of guideline recommendations in a tailored real-world setting. Although these studies were designed and initiated separately, patient advocates in the clinic-based study felt that understanding the home circumstances would be beneficial to clinicians making guideline-based recommendations, while the CHWs visiting homes in the second study wanted more communication with treating clinicians. The proposed project combines these interventions by offering all "PA activities", called the Clinic Intervention (CI) and randomizing half to Home Visits (HV). Additionally, in a factorial design half of patients will be randomized to have their clinician receive feedback on guideline-relevant domains recommended for discussion with patients at appointments. The proposed interventions facilitate communication between clinicians and patients, enriched by understanding of the home environment, the unique view of the patient-clinician interaction at appointments, and barriers to asthma management that patients encounter. While the communication focuses on asthma management, it extends to general care coordination of common co-morbidities such as diabetes, hypertension, obesity and patients will be recruited from both primary care and specialty practices. Community Health Navigators (CHNs), who are lay health workers, will deliver the CI in all patients and the HVs in those so randomized. CHNs with close ties to patients' neighborhoods and also embedded in the clinics, will ensure patients' voices are heard in the delivery of guideline-based care and support patients at risk for health disparities, e. g., older adults, those with comorbidities, low income or limited literacy.
In a randomized controlled factorial trial, adults with uncontrolled asthma living in low-income urban neighborhoods will be offered 18-months participation in four groups of 100 each (1) CI only, (2) CI plus Home Visits (HV), (3) CI and clinician feedback, and (4) CI + HV + clinician feedback. Patients will be evaluated quarterly for 12 months and then observed for 6 months to assess sustainability of the intervention. The investigators will estimate:
Specific Aim 1: improvement over time of within-group (before-after in four groups) asthma outcomes (asthma control, quality of life, ED visits, hospitalizations, prednisone bursts) Specific Aim 2: across group differences in improvement over time in asthma outcomes; Specific Aim 3: the costs associated with each of the intervention, and the investigators will conduct a cost-offset analysis to determine which intervention costs are offset by savings attributable to reductions in ED, hospitalizations or other visits for asthma control and other outcomes.
Exploratory Aim: changes in behavior from the interventions using interviews of clinicians and patients.
Hypothesis and Impact: The investigators hypothesize improved outcomes in asthma patients through enhanced communication of patient and clinician, clinician attention to home environmental exposure, and clinician consideration of the guidelines, at a program cost offset by lower patient health care utilization.
- Conditions
- Asthma
- Being tested
- Clinical intervention, Feedback
- Medical subject headings
- Asthma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Clinical interventionBehavioural
Also called Home Visit
The community health navigator will ask patient to produce medications, to indicate if there are current smokers in the home, to look for structural problems within the home, presence of pests, allergens, pollutants. Pt will be asked to produce their current medications. At the end a report will be written for the clinician.
FeedbackBehavioural
The community health navigator will give the clinician real-time feedback on guideline-related health.
| Study group | Role | What they receive |
|---|---|---|
| Clinical intervention | Active comparator | Clinical health navigator, a community health worker, facilitates preparation for, attends, and confirms patients's understanding of an office visit. Receives: Behavioral: Clinical intervention; Behavioral: Feedback |
| Clinical intervention AND Home Visit | Experimental | Patient receives Clinical intervention and Home visits. Care coordination activities occur taking into account the home environment, its social and physical characteristics. Receives: Behavioral: Clinical intervention; Behavioral: Feedback |
| Clinical intervention AND Feedback | Experimental | Not described Receives: Behavioral: Clinical intervention; Behavioral: Feedback |
| Clinical intervention AND Home Visit AND Feedback | Experimental | Not described Receives: Behavioral: Clinical intervention; Behavioral: Feedback |
What is being measured
The primary outcome is the main question the study is designed to answer.
Asthma Control at baseline
Asthma Control Questionnaire. The questionnaire has a numerical result 0 - 6 based on response to questionnaire, with lower number indicating better control
Measured: At randomization
Asthma Control at 3 months
Asthma Control Questionnaire. The questionnaire has a numerical result 0 - 6 based on response to questionnaire, with lower number indicating better control
Measured: 3 months
Asthma Control at 6 months
Asthma Control Questionnaire. The questionnaire has a numerical result 0 - 6 based on response to questionnaire, with lower number indicating better control
Measured: 6 months
Asthma Control at 9 months
Asthma Control Questionnaire. The questionnaire has a numerical result 0 - 6 based on response to questionnaire, with lower number indicating better control
Measured: 9 months
Asthma Control at 12 months
Asthma Control Questionnaire. The questionnaire has a numerical result 0 - 6 based on response to questionnaire, with lower number indicating better control
Measured: 12 months
Asthma Control at 15 months
Asthma Control Questionnaire. The questionnaire has a numerical result 0 - 6 based on response to questionnaire, with lower number indicating better control
Measured: 15 months
Asthma Control at 18 months
Asthma Control Questionnaire. The questionnaire has a numerical result 0 - 6 based on response to questionnaire, with lower number indicating better control
Measured: 18 months
Secondary outcomes (20)
hospitalizations for asthma
number of hospitalizations as indicated in the electronic medical record. If no record is available, the patient's report and verified if possible with patients' record from the outside institution will be used
Measured: hospitalizations at 3 months
hospitalizations for asthma
Number of hospitalizations as indicated in the electronic medical record. If no record is available, patient's report and verified if possible with patients' record from the outside institution will be used.
Measured: hospitalizations at 6 months
hospitalizations for asthma
Number of hospitalizations as indicated in the electronic medical record. If no record is available, patient's report and verified if possible with patients' record from the outside institution will be used.
Measured: hospitalizations at 9 months
hospitalizations for asthma
Number of hospitalizations as indicated in the electronic medical record. If no record is available, patient's report and verified if possible with patients' record from the outside institution will be used.
Measured: hospitalizations at 12 months
hospitalizations for asthma
Number of hospitalizations as indicated in the electronic medical record. If no record is available, patient's report and verified if possible with patients' record from the outside institution will be used.
Measured: hospitalizations at 15 months
hospitalizations for asthma
Number of hospitalizations as indicated in the electronic medical record. If no record is available, patient's report and verified if possible with patients' record from the outside institution will be used.patient's report and verified if possible with patients' record from the outside institution
Measured: hospitalizations at 18 months
Emergency Department (ED) visits for asthma
Number of ED visits as indicated in the electronic medical record. If no record is available patient's report and verified if possible with patients' record from the outside institution will be used.
Measured: 3 months
Emergency Department (ED) visits for asthma
Number of ED visits as indicated in the electronic medical record. If no record is available patient's report and verified if possible with patients' record from the outside institution will be used.
Measured: 6 months
Emergency Department (ED) visits for asthma
Number of ED visits as indicated in the electronic medical record. If no record is available patient's report and verified if possible with patients' record from the outside institution will be used.
Measured: 9 months
Emergency Department (ED) visits for asthma
Number of ED visits as indicated in the electronic medical record. If no record is available patient's report and verified if possible with patients' record from the outside institution will be used. report and verified if possible with patients' record from the outside institution
Measured: 12 months
Emergency Department (ED) visits for asthma
Number of ED visits as indicated in the electronic medical record. If no record is available patient's report and verified if possible with patients' record from the outside institution will be used.
Measured: 15 months
Emergency Department (ED) visits for asthma
Number of ED visits as indicated in the electronic medical record. If no record is available patient's report and verified if possible with patients' record from the outside institution will be used.
Measured: 18 months
asthma-related quality of life
Score is the mean of the 15-items each scored 1-7. Higher score indicates better quality of life.
Measured: 3 months
asthma-related quality of life
Score is the mean of the 15-items each scored 1-7. Higher score indicates better quality of life.
Measured: 6 months
asthma-related quality of life
Score is the mean of the 15-items each scored 1-7. Higher score indicates better quality of life.
Measured: 9 months
asthma-related quality of life
Score is the mean of the 15-items each scored 1-7. Higher score indicates better quality of life.
Measured: 12 months
asthma-related quality of life
Score is the mean of the 15-items each scored 1-7. Higher score indicates better quality of life.
Measured: 15 months
asthma-related quality of life
Score is the mean of the 15-items each scored 1-7. Higher score indicates better quality of life.
Measured: 18 months
Forced expiratory volume in 1 second (FEV1)
forced vital capacity in 1 second
Measured: Month 12
Forced expiratory volume in 1 second (FEV1)
forced vital capacity in 1 second
Measured: Month 18
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jul 2019
- Study start21 Aug 2019
- Primary completion20 Jan 2025
- Study completion30 Apr 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AsthmaStudies of the same condition, open and under way.
- More trials run by University of PennsylvaniaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Factorial
- Model description
- All patients will receive the clinical intervention (CI). In a 2-factor, 2-level factorial design, patients will be randomized to one of four groups by home visitor (HV) and/or physician feedback(CF) intervention: CI + HV, CI + CF, CI + HV + CF, CI. Well-suited for the investigation of the separate components of an intervention, a factorial design permits simple and powerful comparisons between the two factors (home visitor (HV) and clinician feedback CF), cell specific contrasts (the addition of home visitors among patients who have no physician feedback), and the interaction of both interventions. Each patient will be followed over time, so that the additional power of the factorial design will complement the confounder control inherent in randomization plus longitudinal analysis.
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 367 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Pennsylvania
- Sponsor type
- University, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- Responsible party
- Principal investigator, Andrea Apter, University of Pennsylvania
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04023422
- Sponsor's protocol ID
- R01HL143364
- Acronym
- HAP3
- Status last verified
- May 2025
- First submitted
- 12 Jul 2019
- Last updated
- 18 May 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinic Navigation and Home Visits to Improve Guideline-based Care and Outcomes in Low Income Minority Adults With Asthma
- ClinicalTrials.gov ID
- NCT04023422
- Acronym / sponsor ID
- HAP3 / R01HL143364
- Conditions
- Asthma
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 367 participants (actual)
- Lead sponsor
- University of PennsylvaniaUniversity, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- Study start
- 21 Aug 2019 (actual)
- Primary completion
- 20 Jan 2025 (actual)
- Study completion
- 30 Apr 2026 (estimated)
- First posted
- 17 Jul 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Asthma-related deaths are more numerous among low-income minority patients and older adults with chronic diseases. Guidelines for asthma management have not addressed the needs of these groups. The investigators recently demonstrated the feasibility, acceptability, and evidence of effectiveness of two interventions to improve access to care, patient-provider communication, and asthma outcomes: 1) CI: clinic intervention using a patient advocate to prepare for, attend, and confirm understanding of an office visit, and 2) HV: home visits for care coordination and informing clinicians of home barriers to managing asthma is associated with subsequent improvement in asthma outcomes. This project explores whether these interventions can be combined for greater effectiveness, delivery of guideline-based asthma care, and outcomes in low-income minority patients.
In a randomized controlled factorial trial, 400 adults with uncontrolled asthma living in low-income urban neighborhoods are offered 18-months' participation: 12 months of clinical intervention and 6 months of evaluation to monitor sustainability of interventions and outcomes. Patients will be randomized to 1) a patient advocate and (2) an advocate and home visits, (3) an advocate and real-time feedback to the asthma provider (clinician) at each clinic visit of guidelines-relevant relevant information, and 4) (2), and (3). Interventions will be delivered by a community health worker. The study estimates Specific Aim 1: improvement over time of within-group (before-after in four groups) asthma outcomes (asthma control, quality of life, ED visits, hospitalizations, prednisone bursts) Specific Aim 2: across group differences in improvement over time in asthma outcomes; Specific Aim 3: the costs associated with each of the interventions. A cost-offset analysis will determine which intervention costs are offset by savings attributable to reductions in ED, hospitalization or other visits for asthma control and other outcomes.
Exploratory Aim: changes in behavior from the interventions using interviews of clinicians and patients.
Investigators hypothesize that improved outcomes in asthma patients will result from enhanced patient-clinician communication, clinician attention to home environmental exposures, and clinician consideration of the guidelines, at a program cost offset by lower patient health care utilization.
Detailed description
Asthma, a chronic but treatable disease, affects 18.7 million US adults. Asthma-related deaths, hospitalizations, and ED visits are more prevalent in low-income and minority patients, especially African Americans and particularly among older adults, many with co-morbidities.
The Expert Panel Report 3 (EPR3) Guidelines for Asthma Diagnosis and Management, currently undergoing revision, is primarily directed at children and young adults. It overlooks older patients, many with comorbidities and many who live in poverty. Action plans are infrequently used and their benefits, strongly recommended by guidelines, have not been evaluated in older or low-income minority adults. Regular use of inhaled steroids, endorsed by the Guidelines for all but the mildest asthma is limited by social and economic barriers, e.g. cost and accessibility of medication. Failure of guidelines to address the barriers of poverty, limited education, poor housing and communication infrastructure, and suboptimal public transportation may promote non-adherence by clinicians.
For these vulnerable adults, the investigators recently demonstrated the feasibility, acceptability, and evidence of effectiveness of two separate interventions to improve access to care, patient-provider communication, and asthma outcomes: 1) a patient advocate (PA) (HAP2 Study (R18 HL116285)) to prepare for, attend, and confirm understanding of an office visit, and 2) community health workers (CHWs) (ARC Study (PCORI AS 1307-05218)) to assess home barriers to asthma management and coordinate care between home and clinic. Both protocols, well-accepted by patients and clinicians, allow prompting, delivery, and testing of guideline recommendations in a tailored real-world setting. Although these studies were designed and initiated separately, patient advocates in the clinic-based study felt that understanding the home circumstances would be beneficial to clinicians making guideline-based recommendations, while the CHWs visiting homes in the second study wanted more communication with treating clinicians. The proposed project combines these interventions by offering all "PA activities", called the Clinic Intervention (CI) and randomizing half to Home Visits (HV). Additionally, in a factorial design half of patients will be randomized to have their clinician receive feedback on guideline-relevant domains recommended for discussion with patients at appointments. The proposed interventions facilitate communication between clinicians and patients, enriched by understanding of the home environment, the unique view of the patient-clinician interaction at appointments, and barriers to asthma management that patients encounter. While the communication focuses on asthma management, it extends to general care coordination of common co-morbidities such as diabetes, hypertension, obesity and patients will be recruited from both primary care and specialty practices. Community Health Navigators (CHNs), who are lay health workers, will deliver the CI in all patients and the HVs in those so randomized. CHNs with close ties to patients' neighborhoods and also embedded in the clinics, will ensure patients' voices are heard in the delivery of guideline-based care and support patients at risk for health disparities, e. g., older adults, those with comorbidities, low income or limited literacy.
In a randomized controlled factorial trial, adults with uncontrolled asthma living in low-income urban neighborhoods will be offered 18-months participation in four groups of 100 each (1) CI only, (2) CI plus Home Visits (HV), (3) CI and clinician feedback, and (4) CI + HV + clinician feedback. Patients will be evaluated quarterly for 12 months and then observed for 6 months to assess sustainability of the intervention. The investigators will estimate:
Specific Aim 1: improvement over time of within-group (before-after in four groups) asthma outcomes (asthma control, quality of life, ED visits, hospitalizations, prednisone bursts) Specific Aim 2: across group differences in improvement over time in asthma outcomes; Specific Aim 3: the costs associated with each of the intervention, and the investigators will conduct a cost-offset analysis to determine which intervention costs are offset by savings attributable to reductions in ED, hospitalizations or other visits for asthma control and other outcomes.
Exploratory Aim: changes in behavior from the interventions using interviews of clinicians and patients.
Hypothesis and Impact: The investigators hypothesize improved outcomes in asthma patients through enhanced communication of patient and clinician, clinician attention to home environmental exposure, and clinician consideration of the guidelines, at a program cost offset by lower patient health care utilization.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Single blind (investigator)
- Number of arms
- 4
- Model description
- All patients will receive the clinical intervention (CI). In a 2-factor, 2-level factorial design, patients will be randomized to one of four groups by home visitor (HV) and/or physician feedback(CF) intervention: CI + HV, CI + CF, CI + HV + CF, CI. Well-suited for the investigation of the separate components of an intervention, a factorial design permits simple and powerful comparisons between the two factors (home visitor (HV) and clinician feedback CF), cell specific contrasts (the addition of home visitors among patients who have no physician feedback), and the interaction of both interventions. Each patient will be followed over time, so that the additional power of the factorial design will complement the confounder control inherent in randomization plus longitudinal analysis.
| Arm | Type | Receives |
|---|---|---|
| Clinical intervention | Active comparator | Behavioral: Clinical intervention, Behavioral: FeedbackClinical health navigator, a community health worker, facilitates preparation for, attends, and confirms patients's understanding of an office visit. |
| Clinical intervention AND Home Visit | Experimental | Behavioral: Clinical intervention, Behavioral: FeedbackPatient receives Clinical intervention and Home visits. Care coordination activities occur taking into account the home environment, its social and physical characteristics. |
| Clinical intervention AND Feedback | Experimental | Behavioral: Clinical intervention, Behavioral: Feedback |
| Clinical intervention AND Home Visit AND Feedback | Experimental | Behavioral: Clinical intervention, Behavioral: Feedback |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Female or male > 18 years and living in a Philadelphia neighborhood in which at least 20% of households have incomes below the federal poverty level (19104, 19120, 19121, 19122, 19124, 19125, 19131, 19132, 19133, 19134, 19139, 19140, 19141, 19142, 19143, 19144, 19145, 19146, 19153, 19151)
- A patient in a participating clinic
- Doctor's diagnosis of asthma
- Prescribed an inhaled corticosteroid for asthma
- Required prednisone or an Emergency Department (ED) visit or hospitalization for asthma within 12 months before enrollment.
Key exclusion criteria (3 listed)
- Severe psychiatric or cognitive problems making it impossible to understand or carry out the protocol;
- Excluded are those with other chronic lung diseases: lung cancer, cystic fibrosis, heart failure, chronic bronchitis, pulmonary hypertension, a candidate or recipient for lung transplant, a history of bronchial thermoplasty.
- Excluded are those with more than 20 pack year tobacco use.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Clinical interventionAlso: Home VisitThe community health navigator will ask patient to produce medications, to indicate if there are current smokers in the home, to look for structural problems within the home, presence of pests, allergens, pollutants. Pt will be asked to produce their current medications. At the end a report will be written for the clinician. | Behavioural | Clinical intervention, Clinical intervention AND Feedback, Clinical intervention AND Home Visit, Clinical intervention AND Home Visit AND Feedback |
| FeedbackThe community health navigator will give the clinician real-time feedback on guideline-related health. | Behavioural | Clinical intervention, Clinical intervention AND Feedback, Clinical intervention AND Home Visit, Clinical intervention AND Home Visit AND Feedback |
Primary outcome
Asthma Control at baseline
Time frame: At randomization
Asthma Control Questionnaire. The questionnaire has a numerical result 0 - 6 based on response to questionnaire, with lower number indicating better control
Asthma Control at 3 months
Time frame: 3 months
Asthma Control Questionnaire. The questionnaire has a numerical result 0 - 6 based on response to questionnaire, with lower number indicating better control
Asthma Control at 6 months
Time frame: 6 months
Asthma Control Questionnaire. The questionnaire has a numerical result 0 - 6 based on response to questionnaire, with lower number indicating better control
Asthma Control at 9 months
Time frame: 9 months
Asthma Control Questionnaire. The questionnaire has a numerical result 0 - 6 based on response to questionnaire, with lower number indicating better control
Asthma Control at 12 months
Time frame: 12 months
Asthma Control Questionnaire. The questionnaire has a numerical result 0 - 6 based on response to questionnaire, with lower number indicating better control
Asthma Control at 15 months
Time frame: 15 months
Asthma Control Questionnaire. The questionnaire has a numerical result 0 - 6 based on response to questionnaire, with lower number indicating better control
Asthma Control at 18 months
Time frame: 18 months
Asthma Control Questionnaire. The questionnaire has a numerical result 0 - 6 based on response to questionnaire, with lower number indicating better control
20 secondary outcomes
hospitalizations for asthma
Time frame: hospitalizations at 3 months
hospitalizations for asthma
Time frame: hospitalizations at 6 months
hospitalizations for asthma
Time frame: hospitalizations at 9 months
hospitalizations for asthma
Time frame: hospitalizations at 12 months
hospitalizations for asthma
Time frame: hospitalizations at 15 months
hospitalizations for asthma
Time frame: hospitalizations at 18 months
Emergency Department (ED) visits for asthma
Time frame: 3 months
Emergency Department (ED) visits for asthma
Time frame: 6 months
Emergency Department (ED) visits for asthma
Time frame: 9 months
Emergency Department (ED) visits for asthma
Time frame: 12 months
Emergency Department (ED) visits for asthma
Time frame: 15 months
Emergency Department (ED) visits for asthma
Time frame: 18 months
asthma-related quality of life
Time frame: 3 months
asthma-related quality of life
Time frame: 6 months
asthma-related quality of life
Time frame: 9 months
asthma-related quality of life
Time frame: 12 months
asthma-related quality of life
Time frame: 15 months
asthma-related quality of life
Time frame: 18 months
Forced expiratory volume in 1 second (FEV1)
Time frame: Month 12
Forced expiratory volume in 1 second (FEV1)
Time frame: Month 18
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 May 2025.
Related trials for Asthma
RecruitingObservational study
Role of Genetic Factors in the Development of Lung Disease
Cystic Fibrosis, Pulmonary Fibrosis
RecruitingPhase 2
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
Asthma
RecruitingObservational study
A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice
Asthma
RecruitingPhase 3
A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)
Asthma
Not yet recruitingPhase 4
Novel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate
Asthma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Clinical intervention and Feedback in people with Asthma, run by University of Pennsylvania at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 18 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Asthma Control at baseline (time frame: At randomization). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 May 2025; AzTrials last refreshed its copy on 6 Nov 2026.